Heat Biologics Inc (NASDAQ:HTBX) Appoints Dr. Jeff Hutchins As New Chief Operating Officer

Heat Biologics Inc (NASDAQ:HTBX) has appointed Dr. Jeff Hutchins as its Chief Operating Officer. Dr. Hutchins was previously CSO and SVP, Pre-clinical Development with the company. In his new role, he will lead product development initiatives for Heat Biologic and its Pelican Therapeutics subsidiary firm. The management view Jeff Wolf, the CEO of Heat Biologics, […]

Heat Biologics, Inc. (NASDAQ:HTBX) Manages To Beat Phase 1 In Lung Cancer Combo Experiment

Heat Biologics, Inc. (NASDAQ:HTBX) reported that it is has managed the safety and efficacy endpoint in the Phase 1b trial. It has achieved to get the approval to proceed to Phase 2. The experiment details The company is leading in development of immunotherapies which are meant to activate the immune systems of patients against cancer. […]

Heat Biologics Inc (NASDAQ:HTBX) Expects To Initiate Vesigenurtacel-L Phase 2 Clinical Trials In 4Q2014

Boston, MA 10/03/2014 (wallstreetpr) – Heat Biologics Inc (NASDAQ:HTBX) said that it had completed the enrollment process of Phase 1 clinical trial studies of Vesigenurtacel-L. It has given the treatment to nine patients in the clinical trials. The trial is meant for testing the medication for treating Bladder Cancer. With the completion of Phase 1 trial, […]

Stock Alert: Tower Semiconductor Ltd. (USA) (NASDAQ:TSEM); Heat Biologics Inc (NASDAQ:HTBX) And EnvivioInc (NASDAQ:ENVI)

Boston, MA 03/21/2014 (wallstreetpr) –Tower Semiconductor Ltd. (USA) (NASDAQ:TSEM), which is a specialty foundry dedicated to the manufacture of semiconductors, has entered into a definitive agreement with specific existing US as well as offshore institutional holders. As per this agreement, Tower will issue unsecured bonds in place for approximately $45 million in aggregate principal amount […]

Stock Highlights: Heat Biologics Inc (NASDAQ:HTBX); Growlife Inc (OTCBB:PHOT) And, Galena Biopharma Inc (NASDAQ:GALE)

Boston, MA 03/20/2014 (wallstreetpr) – Heat Biologics Inc (NASDAQ:HTBX) soared by more than 9% on Wednesday after it reported to have submitted a revised protocol to the FDA in relation to its Phase II trial of HS-110 drug. The company’s HS-110 drug is aimed at treating non-small cell cancer. The drug useslung-cancer cells that are […]